Hematologic Oncology | Specialty

Differential Diagnosis and Staging of Follicular Lymphoma

January 28th 2020

Dr. Vusirikala on Ongoing Research With Blinatumomab in ALL

January 28th 2020

Madhuri Vusirikala, MD, professor of internal medicine in the Division of Hematology/Oncology at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses ongoing research with blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).

Long-Term Data, Novel Regimens Showcase Progress in ALL

January 27th 2020

Madhuri Vusirikala, MD, discusses recent changes in the treatment paradigm of acute lymphoblastic leukemia, based on data from the 2019 ASH Annual Meeting.

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

January 27th 2020

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Novel Strategies and Agents Emerge in AML Paradigm

January 25th 2020

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.

Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin Lymphoma

January 24th 2020

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Novel Regimens Generate Excitement in Lymphoma Treatment Paradigms

January 23rd 2020

Narendranath Epperla, MD, MS, reflects on recent advances in Hodgkin lymphoma and non-Hodgkin lymphoma.

Dr. Vusirikala on the Role of MRD in ALL

January 23rd 2020

Madhuri Vusirikala, MD, discusses the role of minimal residual disease in acute lymphoblastic leukemia.

BiTEs, CAR T-Cell Therapy Enhance ALL Armamentarium, But Questions Remain

January 23rd 2020

Lloyd Damon, MD, discusses the evolution of the treatment paradigm in acute lymphoblastic leukemia.

Polatuzumab Vedotin Approved in Europe for Relapsed/Refractory DLBCL

January 22nd 2020

The European Commission has granted a conditional marketing authorization to polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for hematopoietic stem cell transplant.

Dr. Mims on the Emergence of Targeted Therapy in AML

January 22nd 2020

Alice S. Mims, MD, discusses the emergence of targeted therapy in acute myeloid leukemia treatment.

Dr. Moskowitz on Important Updates in Hodgkin Lymphoma

January 21st 2020

Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.

ASH 2019 Data Cement Current Treatment Approaches in Hodgkin, T-Cell Lymphoma

January 21st 2020

Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.

Targeting the Hedgehog Pathway Holds Promises and Pitfalls

January 18th 2020

Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.

Dr. Brown on the Success of Blinatumomab in the AALL 1331 Trial

January 17th 2020

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

January 17th 2020

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

NICE Rejects Treatments for Head and Neck Cancer and AML

January 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

Dr. Mims on Developed Mutations in AML

January 15th 2020

Alice S. Mims, MD, discusses developed resistance in acute myeloid leukemia.

Dr. Allen on Treatment Options in Advanced-Stage Hodgkin Lymphoma

January 13th 2020

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

OSUCCC-James Oncologists Share Ongoing Research Efforts in Hematologic Malignancies

January 11th 2020

Experts from The Ohio State University Comprehensive Cancer Center–James highlighted exciting research being conducted at their institution.